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Dual Antiplatelet Therapy After
Drug-Eluting Stent Implantation
Chasing a Mirage*Matthew J. Price, MDT he optimal treatment duration of aspirin anda P2Y12 receptor antagonist after percuta-neous coronary intervention (PCI) has vexed
cardiologists since the introduction of drug-eluting
stents (DES) approximately a decade ago. A short
(2- to 4-week) course of aspirin and a thienopyridine
after elective implantation of a bare-metal stent
became the standard of care by default from random-
ized trials that observed subjects for only a short
period after PCI (1,2), not from studies that compared
different treatment durations. An ongoing hazard of
late stent thrombosis was observed when thienopyri-
dine therapy was withdrawn beyond 3 to 6 months
after implantation of ﬁrst-generation DES (3), and
histopathological studies linked these events to
the presence of inﬂammation, delayed endotheli-
alization, and neoatherosclerosis (4,5). The current
consensus, codiﬁed by the American College of Car-
diology Foundation/American Heart Association/
Society for Cardiovascular Angiography and Interven-
tions PCI guidelines, is to treat DES patients with at
least 12 months of dual antiplatelet therapy (DAPT),
unless the risk of morbidity from bleeding outweighs
the anticipated beneﬁt afforded by continued P2Y12
inhibitor therapy (6). From a philosophical perspec-
tive, the unnerving experience with ﬁrst-generation*Editorials published in the Journal of the American College of Cardiology
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Eli Lilly and Company.DES shifted the priorities of the interventional cardi-
ologist at the time of discharge from treating the
patient to treating the stent.
The second-generation DES are associated with
better endothelial healing, likely due to differences in
strut design, polymer quantity and composition, use
of rapamycin analogues, and drug-release kinetics
(7). Network meta-analysis and post-randomization
analyses of varying durations of thienopyridine
treatment suggest that late stent thrombosis is also
less frequent with the newer DES, raising the ques-
tion of whether a 12-month regimen of aspirin and a
P2Y12 antagonist is still required in patients with
stable coronary artery disease undergoing stent im-
plantation (8). Although several trials have attempted
to assess the safety of more abbreviated courses
of a thienopyridine after implantation of second-
generation DES, these trials are hampered by lack
of power and open-label designs. The results of
the DAPT (Dual Antiplatelet Therapy) study added
further confusion for many practitioners (9). This
large, placebo-controlled trial, which included both
ﬁrst- and second-generation DES, found that con-
tinued administration of a thienopyridine beyond
the consensus 12-month duration reduced the risk
of stent thrombosis and spontaneous myocardial
infarction (MI) but was associated with an increased
risk of bleeding.SEE PAGE 1298In this issue of the Journal, Giustino et al. (10)
address this confusion with a meta-analysis of the
effects of different durations of DAPT on ischemic
and bleeding outcomes after DES implantation. The
investigators included a total of 10 studies involving
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131232,135 patients. Among those studies, the duration of
“short” DAPT ranged from 3 to 12 months, and the
duration of “longer” DAPT ranged from 12 to 48
months. The investigators found that short DAPT was
associated with a signiﬁcantly higher rate of stent
thrombosis (odds ratio: 1.71; 95% conﬁdence interval:
1.36 to 2.32) but with less clinically signiﬁcant
bleeding (odds ratio: 0.63; 95% conﬁdence interval:
0.52 to 0.72). Pooling the data from the trials demon-
strated that for every episode of stent thrombosis
prevented by longer DAPT, w2.4 clinically signiﬁcant
episodes of bleeding would occur. Second-generation
DES substantially attenuated the increased risk of
stent thrombosis with short DAPT, and therefore, the
authors warn that “the prevention of a single episode
of late stent thrombosis will require exposing a
greater number of patients with a second-generation
DES to potentially serious bleeding harm.”
With this sobering admonition regarding the prac-
tical implications of adopting extended P2Y12 inhibi-
tion in the current era of second-generation DES,
the investigators cast doubt on the appropriate
application of the DAPT trial ﬁndings, in which the
risk reduction in ischemic events beyond 1 year of
thienopyridine therapy was consistent across stent
type (9). However, there are several issues with the
current study that make the validity of its ﬁndings
uncertain. First, the included trials are clinically
and methodologically heterogeneous, suggesting
that they are not poolable. The trials can be broadly
divided into 2 groups with different purposes: those
that were designed to test whether the duration of
DAPT could be safely shortened (e.g., 3 to 6 months
vs. 6 to 12 months) and those that were performed
to investigate whether DAPT beyond the consensus
duration could improve outcomes (12 months vs.
30 months). The signiﬁcant interaction between the 2
clinical groupings and the treatment effect of DAPT
duration supports the presence of such heterogeneity
and suggests that pooling may have diluted the pro-
tective effect of extended thienopyridine therapy.
The comparison between stent generations is fraught
with even more uncertainty, as the DAPT trial is the
only study included in the analysis that examined
the beneﬁt of continued thienopyridine treatment
beyond 12 months with both generations of DES.
Therefore, the meta-analysis cannot provide greater
insight than the DAPT trial alone regarding the
risk and beneﬁt of extended therapy with second-
generation DES. Sensitivity analyses further suggest
that the meta-analysis ﬁndings are not robust: after
excluding the DAPT trial, the effects of different
treatment durations on stent thrombosis and on
mortality were of borderline signiﬁcance and neutral,respectively. Finally, the investigators perform an
elegant analysis by using standardized incident ratios
to quantify the trade-off between a reduction in
stent thrombosis and increased “clinically signiﬁ-
cant” bleeding with continued DAPT. However, this
approach was limited in 2 respects: ﬁrst, it assumed
that the clinician and patient view these events with
equal weight, and second, the calculation ignored
the protection from spontaneous MIs unrelated to
the index DES, which in the DAPT trial accounted
for more than one-half the ischemic reduction asso-
ciated with continued thienopyridine therapy beyond
12 months.
Despite these limitations, several important con-
clusions can be drawn from the efforts of Giustino
et al. (10). The analysis of abbreviated duration of
DAPT support the hypothesis that it is reasonably safe
to treat second-generation DES with a 12-month or
briefer (3- to 6-month) course of DAPT, if required,
with the caveat that the safety of noncardiac surgery
early after discontinuation was not evaluated. The
inﬂuence of anatomic complexity and clinical char-
acteristics are unknown, and evidence from a meta-
analysis is not as robust as that from a large
randomized clinical trial. However, an adequately
powered randomized trial will be difﬁcult to complete,
as exempliﬁed by the ISAR-SAFE (Intracoronary
Stenting and Antithrombotic Regimen: Safety and
Efﬁcacy of 6 Months Dual Antiplatelet Therapy After
Drug-Eluting Stenting) trial, which was prema-
turely halted due to slow recruitment and lower-
than-expected event rates (11).
Treating patients who have received a newer DES
with extended therapy beyond 12 months reduces
stent-related and non–stent-related ischemic events
but at the cost of more bleeding. The net balance
between these events for the individual patient is
the conundrum that has yet to be convincingly
answered. Although the current study (10) may have
overestimated the degree to which second-generation
DES attenuates the clinical beneﬁt of extended DAPT,
the totality of data strongly suggests that the risk
of late stent thrombosis is substantially lower with
these stents, which will narrow the therapeutic
window for extended P2Y12 antagonism even if it re-
duces the relative risk reduction of stent thrombosis
consistently across DES type (9). The magnitude of
the reduction in non–stent-related ischemic events
is therefore a major contributor to the risk/beneﬁt
calculus for the particular patient treated with ex-
tended therapy. The existence of a non–stent-related
ischemic reduction is supported by CREDO (Clopi-
dogrel for the Reduction of Events During Observa-
tion) (12), a post-hoc analysis of the CHARISMA
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1313(Clopidogrel for High Atherothrombotic Risk and
Ischemic Stabilization, Management, and Avoidance)
trial (13), the DAPT trial (9), and now PEGASUS–TIMI 54
(Prevention of Cardiovascular Events in Patients
With Prior Heart Attack Using Ticagrelor Compared
to Placebo on a Background of Aspirin–Thrombolysis
In Myocardial Infarction 54) (14). The next hurdle is
to quantify the ischemic beneﬁt unrelated to the
stent for the particular DES patient, which will likely
depend on a spectrum of clinical, demographic,
and possibly genetic characteristics. In addition,
targeted P2Y12 inhibition within a range that reducesischemia but mitigates bleeding remains a tanta-
lizing, yet unproven, approach to enhance long-term
safety (15). Once these challenges are overcome,
interventional cardiologists will be able to stop
treating the stent and begin (again) to treat the
patient.
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